nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—urinary bladder cancer	0.42	1	CtDrD
Pazopanib—FGFR3—urinary bladder cancer	0.264	1	CbGaD
Pazopanib—UGT1A1—Etoposide—urinary bladder cancer	0.0141	0.119	CbGbCtD
Pazopanib—ABCB1—Mitomycin—urinary bladder cancer	0.0136	0.114	CbGbCtD
Pazopanib—ABCG2—Fluorouracil—urinary bladder cancer	0.00931	0.0781	CbGbCtD
Pazopanib—ABCG2—Carboplatin—urinary bladder cancer	0.00925	0.0776	CbGbCtD
Pazopanib—ABCG2—Cisplatin—urinary bladder cancer	0.00791	0.0663	CbGbCtD
Pazopanib—ABCG2—Etoposide—urinary bladder cancer	0.00777	0.0652	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—urinary bladder cancer	0.00646	0.0542	CbGbCtD
Pazopanib—CYP3A4—Thiotepa—urinary bladder cancer	0.00619	0.0519	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—urinary bladder cancer	0.0053	0.0445	CbGbCtD
Pazopanib—ABCG2—Methotrexate—urinary bladder cancer	0.00513	0.0431	CbGbCtD
Pazopanib—CYP2C8—Fluorouracil—urinary bladder cancer	0.00496	0.0416	CbGbCtD
Pazopanib—CYP2C8—Etoposide—urinary bladder cancer	0.00414	0.0347	CbGbCtD
Pazopanib—ABCB1—Gemcitabine—urinary bladder cancer	0.00392	0.0329	CbGbCtD
Pazopanib—CYP1A2—Fluorouracil—urinary bladder cancer	0.00384	0.0322	CbGbCtD
Pazopanib—CYP1A2—Etoposide—urinary bladder cancer	0.0032	0.0269	CbGbCtD
Pazopanib—ABCB1—Cisplatin—urinary bladder cancer	0.00285	0.0239	CbGbCtD
Pazopanib—ABCB1—Etoposide—urinary bladder cancer	0.0028	0.0235	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—urinary bladder cancer	0.00191	0.016	CbGbCtD
Pazopanib—ABCB1—Methotrexate—urinary bladder cancer	0.00185	0.0155	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—urinary bladder cancer	0.0018	0.0151	CbGbCtD
Pazopanib—CYP3A4—Etoposide—urinary bladder cancer	0.00168	0.0141	CbGbCtD
Pazopanib—PDGFRA—penis—urinary bladder cancer	0.00144	0.0255	CbGeAlD
Pazopanib—FLT1—umbilical vein—urinary bladder cancer	0.00127	0.0225	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00114	0.00961	CbGbCtD
Pazopanib—KDR—umbilical vein—urinary bladder cancer	0.00107	0.019	CbGeAlD
Pazopanib—UGT1A1—urine—urinary bladder cancer	0.000915	0.0162	CbGeAlD
Pazopanib—ITK—prostate gland—urinary bladder cancer	0.000844	0.0149	CbGeAlD
Pazopanib—TAOK1—prostate gland—urinary bladder cancer	0.000768	0.0136	CbGeAlD
Pazopanib—MAP3K9—epithelium—urinary bladder cancer	0.000752	0.0133	CbGeAlD
Pazopanib—SH2B3—prostate gland—urinary bladder cancer	0.000723	0.0128	CbGeAlD
Pazopanib—STK16—prostate gland—urinary bladder cancer	0.000615	0.0109	CbGeAlD
Pazopanib—SH2B3—seminal vesicle—urinary bladder cancer	0.000612	0.0108	CbGeAlD
Pazopanib—FGFR3—prostate gland—urinary bladder cancer	0.000605	0.0107	CbGeAlD
Pazopanib—RIOK2—prostate gland—urinary bladder cancer	0.000605	0.0107	CbGeAlD
Pazopanib—BMPR1B—prostate gland—urinary bladder cancer	0.000599	0.0106	CbGeAlD
Pazopanib—MAP3K9—female reproductive system—urinary bladder cancer	0.000559	0.00989	CbGeAlD
Pazopanib—STK36—prostate gland—urinary bladder cancer	0.000544	0.00962	CbGeAlD
Pazopanib—PI4KB—prostate gland—urinary bladder cancer	0.000536	0.00948	CbGeAlD
Pazopanib—LIMK2—prostate gland—urinary bladder cancer	0.000526	0.0093	CbGeAlD
Pazopanib—TAOK1—renal system—urinary bladder cancer	0.000524	0.00927	CbGeAlD
Pazopanib—TAOK1—urethra—urinary bladder cancer	0.000514	0.0091	CbGeAlD
Pazopanib—RIOK2—seminal vesicle—urinary bladder cancer	0.000512	0.00906	CbGeAlD
Pazopanib—MAP3K9—vagina—urinary bladder cancer	0.000505	0.00894	CbGeAlD
Pazopanib—SH2B3—urethra—urinary bladder cancer	0.000484	0.00857	CbGeAlD
Pazopanib—FLT4—prostate gland—urinary bladder cancer	0.000472	0.00836	CbGeAlD
Pazopanib—PIP4K2C—prostate gland—urinary bladder cancer	0.00047	0.00832	CbGeAlD
Pazopanib—FGFR1—prostate gland—urinary bladder cancer	0.000466	0.00825	CbGeAlD
Pazopanib—STK36—seminal vesicle—urinary bladder cancer	0.00046	0.00814	CbGeAlD
Pazopanib—PI4KB—seminal vesicle—urinary bladder cancer	0.000453	0.00802	CbGeAlD
Pazopanib—MAP3K2—prostate gland—urinary bladder cancer	0.000445	0.00788	CbGeAlD
Pazopanib—FGFR3—epithelium—urinary bladder cancer	0.000445	0.00787	CbGeAlD
Pazopanib—BMPR1B—epithelium—urinary bladder cancer	0.00044	0.00779	CbGeAlD
Pazopanib—FGF1—prostate gland—urinary bladder cancer	0.00042	0.00743	CbGeAlD
Pazopanib—TAOK1—female reproductive system—urinary bladder cancer	0.000419	0.00742	CbGeAlD
Pazopanib—LCK—prostate gland—urinary bladder cancer	0.000417	0.00738	CbGeAlD
Pazopanib—ITK—vagina—urinary bladder cancer	0.000417	0.00737	CbGeAlD
Pazopanib—FGFR3—renal system—urinary bladder cancer	0.000413	0.0073	CbGeAlD
Pazopanib—FGFR3—urethra—urinary bladder cancer	0.000405	0.00717	CbGeAlD
Pazopanib—RIOK2—urethra—urinary bladder cancer	0.000405	0.00717	CbGeAlD
Pazopanib—CYP1A2—urine—urinary bladder cancer	0.000405	0.00717	CbGeAlD
Pazopanib—PIP4K2C—seminal vesicle—urinary bladder cancer	0.000397	0.00703	CbGeAlD
Pazopanib—FGFR2—prostate gland—urinary bladder cancer	0.000396	0.00701	CbGeAlD
Pazopanib—AURKC—female reproductive system—urinary bladder cancer	0.000389	0.00688	CbGeAlD
Pazopanib—TAOK1—vagina—urinary bladder cancer	0.000379	0.00671	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—urinary bladder cancer	0.000379	0.00671	CbGeAlD
Pazopanib—FLT1—prostate gland—urinary bladder cancer	0.000367	0.0065	CbGeAlD
Pazopanib—PI4KB—renal system—urinary bladder cancer	0.000365	0.00646	CbGeAlD
Pazopanib—STK36—urethra—urinary bladder cancer	0.000364	0.00644	CbGeAlD
Pazopanib—EPHB6—prostate gland—urinary bladder cancer	0.000363	0.00643	CbGeAlD
Pazopanib—PI4KB—urethra—urinary bladder cancer	0.000359	0.00635	CbGeAlD
Pazopanib—SH2B3—vagina—urinary bladder cancer	0.000357	0.00632	CbGeAlD
Pazopanib—PLK4—female reproductive system—urinary bladder cancer	0.000355	0.00629	CbGeAlD
Pazopanib—STK10—prostate gland—urinary bladder cancer	0.000348	0.00615	CbGeAlD
Pazopanib—FLT4—epithelium—urinary bladder cancer	0.000347	0.00614	CbGeAlD
Pazopanib—TAOK3—prostate gland—urinary bladder cancer	0.000346	0.00613	CbGeAlD
Pazopanib—PDGFRA—prostate gland—urinary bladder cancer	0.000344	0.00609	CbGeAlD
Pazopanib—PLK4—Epirubicin—Valrubicin—urinary bladder cancer	0.000337	0.2	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Valrubicin—urinary bladder cancer	0.000337	0.2	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Valrubicin—urinary bladder cancer	0.000337	0.2	CbGdCrCtD
Pazopanib—STK16—female reproductive system—urinary bladder cancer	0.000336	0.00594	CbGeAlD
Pazopanib—FGFR3—female reproductive system—urinary bladder cancer	0.00033	0.00585	CbGeAlD
Pazopanib—RIOK2—female reproductive system—urinary bladder cancer	0.00033	0.00585	CbGeAlD
Pazopanib—UGT1A1—prostate gland—urinary bladder cancer	0.000328	0.00581	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—urinary bladder cancer	0.000327	0.00579	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—urinary bladder cancer	0.000327	0.00579	CbGeAlD
Pazopanib—MAP3K9—lymph node—urinary bladder cancer	0.000327	0.00578	CbGeAlD
Pazopanib—PIP4K2C—urethra—urinary bladder cancer	0.000315	0.00557	CbGeAlD
Pazopanib—FGFR1—urethra—urinary bladder cancer	0.000312	0.00552	CbGeAlD
Pazopanib—FLT1—seminal vesicle—urinary bladder cancer	0.000311	0.0055	CbGeAlD
Pazopanib—KDR—prostate gland—urinary bladder cancer	0.000311	0.0055	CbGeAlD
Pazopanib—MAP2K5—prostate gland—urinary bladder cancer	0.000311	0.0055	CbGeAlD
Pazopanib—FGF1—epithelium—urinary bladder cancer	0.000308	0.00546	CbGeAlD
Pazopanib—EPHB6—seminal vesicle—urinary bladder cancer	0.000307	0.00544	CbGeAlD
Pazopanib—STK16—vagina—urinary bladder cancer	0.000304	0.00537	CbGeAlD
Pazopanib—CSF1R—prostate gland—urinary bladder cancer	0.000303	0.00536	CbGeAlD
Pazopanib—RIOK2—vagina—urinary bladder cancer	0.000299	0.00529	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—urinary bladder cancer	0.000297	0.00526	CbGeAlD
Pazopanib—STK36—female reproductive system—urinary bladder cancer	0.000297	0.00525	CbGeAlD
Pazopanib—CYP3A4—urine—urinary bladder cancer	0.000293	0.00519	CbGeAlD
Pazopanib—TAOK3—seminal vesicle—urinary bladder cancer	0.000293	0.00519	CbGeAlD
Pazopanib—PI4KB—female reproductive system—urinary bladder cancer	0.000292	0.00517	CbGeAlD
Pazopanib—FGFR2—epithelium—urinary bladder cancer	0.000291	0.00515	CbGeAlD
Pazopanib—CYP2D6—urine—urinary bladder cancer	0.000288	0.00511	CbGeAlD
Pazopanib—LIMK2—female reproductive system—urinary bladder cancer	0.000287	0.00508	CbGeAlD
Pazopanib—FGF1—renal system—urinary bladder cancer	0.000286	0.00506	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—urinary bladder cancer	0.000281	0.00497	CbGeAlD
Pazopanib—LCK—urethra—urinary bladder cancer	0.000279	0.00494	CbGeAlD
Pazopanib—KIT—prostate gland—urinary bladder cancer	0.000275	0.00487	CbGeAlD
Pazopanib—FGFR2—renal system—urinary bladder cancer	0.00027	0.00478	CbGeAlD
Pazopanib—FLT1—epithelium—urinary bladder cancer	0.00027	0.00478	CbGeAlD
Pazopanib—ITK—lymph node—urinary bladder cancer	0.000269	0.00477	CbGeAlD
Pazopanib—PDGFRB—prostate gland—urinary bladder cancer	0.000269	0.00476	CbGeAlD
Pazopanib—STK36—vagina—urinary bladder cancer	0.000268	0.00475	CbGeAlD
Pazopanib—PI4KB—vagina—urinary bladder cancer	0.000264	0.00468	CbGeAlD
Pazopanib—MAP2K5—seminal vesicle—urinary bladder cancer	0.000263	0.00465	CbGeAlD
Pazopanib—KDR—seminal vesicle—urinary bladder cancer	0.000263	0.00465	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—urinary bladder cancer	0.00026	0.0046	CbGeAlD
Pazopanib—LIMK2—vagina—urinary bladder cancer	0.00026	0.00459	CbGeAlD
Pazopanib—FLT4—female reproductive system—urinary bladder cancer	0.000258	0.00456	CbGeAlD
Pazopanib—PIP4K2C—female reproductive system—urinary bladder cancer	0.000256	0.00454	CbGeAlD
Pazopanib—CSF1R—seminal vesicle—urinary bladder cancer	0.000256	0.00454	CbGeAlD
Pazopanib—FLT1—renal system—urinary bladder cancer	0.00025	0.00443	CbGeAlD
Pazopanib—FLT1—urethra—urinary bladder cancer	0.000246	0.00435	CbGeAlD
Pazopanib—TAOK1—lymph node—urinary bladder cancer	0.000245	0.00434	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.000244	0.00431	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—urinary bladder cancer	0.000243	0.0043	CbGeAlD
Pazopanib—EPHB6—urethra—urinary bladder cancer	0.000243	0.0043	CbGeAlD
Pazopanib—STK10—renal system—urinary bladder cancer	0.000237	0.00419	CbGeAlD
Pazopanib—TAOK3—renal system—urinary bladder cancer	0.000236	0.00418	CbGeAlD
Pazopanib—PDGFRA—renal system—urinary bladder cancer	0.000235	0.00415	CbGeAlD
Pazopanib—KIT—seminal vesicle—urinary bladder cancer	0.000233	0.00412	CbGeAlD
Pazopanib—PIP4K2C—vagina—urinary bladder cancer	0.000232	0.00411	CbGeAlD
Pazopanib—TAOK3—urethra—urinary bladder cancer	0.000232	0.0041	CbGeAlD
Pazopanib—SH2B3—lymph node—urinary bladder cancer	0.000231	0.00409	CbGeAlD
Pazopanib—FGFR1—vagina—urinary bladder cancer	0.00023	0.00407	CbGeAlD
Pazopanib—FGF1—female reproductive system—urinary bladder cancer	0.000229	0.00405	CbGeAlD
Pazopanib—KDR—epithelium—urinary bladder cancer	0.000228	0.00404	CbGeAlD
Pazopanib—AURKC—lymph node—urinary bladder cancer	0.000227	0.00402	CbGeAlD
Pazopanib—PDGFRB—seminal vesicle—urinary bladder cancer	0.000227	0.00402	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—urinary bladder cancer	0.000225	0.133	CbGdCrCtD
Pazopanib—UGT1A1—renal system—urinary bladder cancer	0.000224	0.00396	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—urinary bladder cancer	0.00022	0.00389	CbGeAlD
Pazopanib—FGFR2—female reproductive system—urinary bladder cancer	0.000216	0.00383	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000215	0.0038	CbGeAlD
Pazopanib—KDR—renal system—urinary bladder cancer	0.000212	0.00375	CbGeAlD
Pazopanib—PLK4—lymph node—urinary bladder cancer	0.000208	0.00368	CbGeAlD
Pazopanib—KDR—urethra—urinary bladder cancer	0.000208	0.00368	CbGeAlD
Pazopanib—MAP2K5—urethra—urinary bladder cancer	0.000208	0.00368	CbGeAlD
Pazopanib—LCK—vagina—urinary bladder cancer	0.000206	0.00364	CbGeAlD
Pazopanib—CSF1R—urethra—urinary bladder cancer	0.000203	0.00359	CbGeAlD
Pazopanib—KIT—epithelium—urinary bladder cancer	0.000202	0.00358	CbGeAlD
Pazopanib—FLT1—female reproductive system—urinary bladder cancer	0.000201	0.00355	CbGeAlD
Pazopanib—PDGFRB—epithelium—urinary bladder cancer	0.000198	0.0035	CbGeAlD
Pazopanib—STK16—lymph node—urinary bladder cancer	0.000196	0.00348	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—urinary bladder cancer	0.000195	0.00345	CbGeAlD
Pazopanib—RIOK2—lymph node—urinary bladder cancer	0.000193	0.00342	CbGeAlD
Pazopanib—BMPR1B—lymph node—urinary bladder cancer	0.000191	0.00339	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.00019	0.00337	CbGeAlD
Pazopanib—STK10—female reproductive system—urinary bladder cancer	0.00019	0.00336	CbGeAlD
Pazopanib—TAOK3—female reproductive system—urinary bladder cancer	0.000189	0.00335	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—urinary bladder cancer	0.000188	0.00333	CbGeAlD
Pazopanib—KIT—renal system—urinary bladder cancer	0.000188	0.00332	CbGeAlD
Pazopanib—SLCO1B1—renal system—urinary bladder cancer	0.000186	0.0033	CbGeAlD
Pazopanib—KIT—urethra—urinary bladder cancer	0.000184	0.00326	CbGeAlD
Pazopanib—PDGFRB—renal system—urinary bladder cancer	0.000183	0.00324	CbGeAlD
Pazopanib—FLT1—vagina—urinary bladder cancer	0.000181	0.00321	CbGeAlD
Pazopanib—PDGFRB—urethra—urinary bladder cancer	0.00018	0.00318	CbGeAlD
Pazopanib—EPHB6—vagina—urinary bladder cancer	0.000179	0.00317	CbGeAlD
Pazopanib—STK36—lymph node—urinary bladder cancer	0.000174	0.00307	CbGeAlD
Pazopanib—STK10—vagina—urinary bladder cancer	0.000172	0.00304	CbGeAlD
Pazopanib—TAOK3—vagina—urinary bladder cancer	0.000171	0.00303	CbGeAlD
Pazopanib—PI4KB—lymph node—urinary bladder cancer	0.000171	0.00303	CbGeAlD
Pazopanib—PDGFRA—vagina—urinary bladder cancer	0.00017	0.00301	CbGeAlD
Pazopanib—KDR—female reproductive system—urinary bladder cancer	0.00017	0.003	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—urinary bladder cancer	0.00017	0.003	CbGeAlD
Pazopanib—LIMK2—lymph node—urinary bladder cancer	0.000168	0.00297	CbGeAlD
Pazopanib—CSF1R—female reproductive system—urinary bladder cancer	0.000165	0.00293	CbGeAlD
Pazopanib—KDR—vagina—urinary bladder cancer	0.000153	0.00271	CbGeAlD
Pazopanib—MAP2K5—vagina—urinary bladder cancer	0.000153	0.00271	CbGeAlD
Pazopanib—ABCG2—prostate gland—urinary bladder cancer	0.000151	0.00267	CbGeAlD
Pazopanib—FLT4—lymph node—urinary bladder cancer	0.000151	0.00267	CbGeAlD
Pazopanib—KIT—female reproductive system—urinary bladder cancer	0.00015	0.00266	CbGeAlD
Pazopanib—PIP4K2C—lymph node—urinary bladder cancer	0.00015	0.00266	CbGeAlD
Pazopanib—CSF1R—vagina—urinary bladder cancer	0.00015	0.00265	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—urinary bladder cancer	0.000149	0.00264	CbGeAlD
Pazopanib—FGFR1—lymph node—urinary bladder cancer	0.000149	0.00263	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—urinary bladder cancer	0.000147	0.0026	CbGeAlD
Pazopanib—MAP3K2—lymph node—urinary bladder cancer	0.000142	0.00252	CbGeAlD
Pazopanib—KIT—vagina—urinary bladder cancer	0.000136	0.0024	CbGeAlD
Pazopanib—FGF1—lymph node—urinary bladder cancer	0.000134	0.00237	CbGeAlD
Pazopanib—LCK—lymph node—urinary bladder cancer	0.000133	0.00236	CbGeAlD
Pazopanib—PDGFRB—vagina—urinary bladder cancer	0.000133	0.00235	CbGeAlD
Pazopanib—ABCG2—seminal vesicle—urinary bladder cancer	0.000128	0.00226	CbGeAlD
Pazopanib—FLT1—lymph node—urinary bladder cancer	0.000117	0.00208	CbGeAlD
Pazopanib—PLK4—Idarubicin—Epirubicin—urinary bladder cancer	0.000117	0.0695	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Epirubicin—urinary bladder cancer	0.000117	0.0695	CbGdCrCtD
Pazopanib—EPHB6—lymph node—urinary bladder cancer	0.000116	0.00205	CbGeAlD
Pazopanib—STK10—lymph node—urinary bladder cancer	0.000111	0.00197	CbGeAlD
Pazopanib—TAOK3—lymph node—urinary bladder cancer	0.000111	0.00196	CbGeAlD
Pazopanib—PDGFRA—lymph node—urinary bladder cancer	0.00011	0.00195	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—urinary bladder cancer	0.000108	0.0643	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—urinary bladder cancer	0.000108	0.0643	CbGdCrCtD
Pazopanib—CYP2C8—renal system—urinary bladder cancer	0.000106	0.00187	CbGeAlD
Pazopanib—ABCG2—urethra—urinary bladder cancer	0.000101	0.00179	CbGeAlD
Pazopanib—KDR—lymph node—urinary bladder cancer	9.92e-05	0.00175	CbGeAlD
Pazopanib—MAP2K5—lymph node—urinary bladder cancer	9.92e-05	0.00175	CbGeAlD
Pazopanib—CYP1A2—renal system—urinary bladder cancer	9.91e-05	0.00175	CbGeAlD
Pazopanib—CSF1R—lymph node—urinary bladder cancer	9.68e-05	0.00171	CbGeAlD
Pazopanib—KIT—lymph node—urinary bladder cancer	8.79e-05	0.00156	CbGeAlD
Pazopanib—PDGFRB—lymph node—urinary bladder cancer	8.58e-05	0.00152	CbGeAlD
Pazopanib—CYP2C8—female reproductive system—urinary bladder cancer	8.48e-05	0.0015	CbGeAlD
Pazopanib—CYP2C8—vagina—urinary bladder cancer	7.67e-05	0.00136	CbGeAlD
Pazopanib—ABCG2—vagina—urinary bladder cancer	7.46e-05	0.00132	CbGeAlD
Pazopanib—ABCB1—prostate gland—urinary bladder cancer	7.45e-05	0.00132	CbGeAlD
Pazopanib—CYP3A4—renal system—urinary bladder cancer	7.17e-05	0.00127	CbGeAlD
Pazopanib—CYP2D6—renal system—urinary bladder cancer	7.06e-05	0.00125	CbGeAlD
Pazopanib—ABCB1—seminal vesicle—urinary bladder cancer	6.3e-05	0.00112	CbGeAlD
Pazopanib—CYP3A4—female reproductive system—urinary bladder cancer	5.74e-05	0.00102	CbGeAlD
Pazopanib—CYP2D6—female reproductive system—urinary bladder cancer	5.65e-05	0.001	CbGeAlD
Pazopanib—ABCB1—epithelium—urinary bladder cancer	5.47e-05	0.000969	CbGeAlD
Pazopanib—ABCB1—renal system—urinary bladder cancer	5.08e-05	0.000899	CbGeAlD
Pazopanib—ABCB1—urethra—urinary bladder cancer	4.99e-05	0.000883	CbGeAlD
Pazopanib—ABCG2—lymph node—urinary bladder cancer	4.82e-05	0.000854	CbGeAlD
Pazopanib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	4.38e-05	0.000674	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—urinary bladder cancer	4.37e-05	0.000672	CcSEcCtD
Pazopanib—Infestation—Methotrexate—urinary bladder cancer	4.37e-05	0.000672	CcSEcCtD
Pazopanib—Pain—Cisplatin—urinary bladder cancer	4.34e-05	0.000668	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	4.33e-05	0.000666	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—urinary bladder cancer	4.29e-05	0.000659	CcSEcCtD
Pazopanib—Dizziness—Thiotepa—urinary bladder cancer	4.28e-05	0.000658	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—urinary bladder cancer	4.27e-05	0.000657	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—urinary bladder cancer	4.26e-05	0.000655	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—urinary bladder cancer	4.19e-05	0.000644	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—urinary bladder cancer	4.18e-05	0.000642	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—urinary bladder cancer	4.17e-05	0.00064	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—urinary bladder cancer	4.16e-05	0.00064	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—urinary bladder cancer	4.15e-05	0.000638	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—urinary bladder cancer	4.15e-05	0.000638	CcSEcCtD
Pazopanib—Somnolence—Etoposide—urinary bladder cancer	4.14e-05	0.000636	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	4.13e-05	0.000635	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—urinary bladder cancer	4.12e-05	0.000634	CcSEcCtD
Pazopanib—Vomiting—Thiotepa—urinary bladder cancer	4.12e-05	0.000633	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—urinary bladder cancer	4.09e-05	0.000629	CcSEcCtD
Pazopanib—Infestation—Epirubicin—urinary bladder cancer	4.09e-05	0.000629	CcSEcCtD
Pazopanib—Rash—Thiotepa—urinary bladder cancer	4.08e-05	0.000628	CcSEcCtD
Pazopanib—Dermatitis—Thiotepa—urinary bladder cancer	4.08e-05	0.000627	CcSEcCtD
Pazopanib—ABCB1—female reproductive system—urinary bladder cancer	4.07e-05	0.00072	CbGeAlD
Pazopanib—Headache—Thiotepa—urinary bladder cancer	4.06e-05	0.000624	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—urinary bladder cancer	4.04e-05	0.000622	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	4.02e-05	0.000617	CcSEcCtD
Pazopanib—Fatigue—Etoposide—urinary bladder cancer	4.01e-05	0.000617	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—urinary bladder cancer	3.99e-05	0.000613	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—urinary bladder cancer	3.99e-05	0.000613	CcSEcCtD
Pazopanib—Pain—Etoposide—urinary bladder cancer	3.98e-05	0.000612	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—urinary bladder cancer	3.97e-05	0.00061	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—urinary bladder cancer	3.94e-05	0.000606	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—urinary bladder cancer	3.92e-05	0.000603	CcSEcCtD
Pazopanib—Asthenia—Gemcitabine—urinary bladder cancer	3.91e-05	0.000601	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—urinary bladder cancer	3.9e-05	0.000599	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—urinary bladder cancer	3.87e-05	0.000596	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	3.87e-05	0.000595	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	3.87e-05	0.000595	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—urinary bladder cancer	3.86e-05	0.000593	CcSEcCtD
Pazopanib—Pruritus—Gemcitabine—urinary bladder cancer	3.85e-05	0.000593	CcSEcCtD
Pazopanib—Nausea—Thiotepa—urinary bladder cancer	3.85e-05	0.000591	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—urinary bladder cancer	3.84e-05	0.000591	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—urinary bladder cancer	3.84e-05	0.00059	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—urinary bladder cancer	3.8e-05	0.000585	CcSEcCtD
Pazopanib—Pruritus—Fluorouracil—urinary bladder cancer	3.79e-05	0.000583	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—urinary bladder cancer	3.78e-05	0.000582	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—urinary bladder cancer	3.78e-05	0.000582	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—urinary bladder cancer	3.74e-05	0.000574	CcSEcCtD
Pazopanib—Diarrhoea—Gemcitabine—urinary bladder cancer	3.73e-05	0.000573	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—urinary bladder cancer	3.69e-05	0.000567	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—urinary bladder cancer	3.69e-05	0.000567	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—urinary bladder cancer	3.69e-05	0.000567	CcSEcCtD
Pazopanib—ABCB1—vagina—urinary bladder cancer	3.68e-05	0.000651	CbGeAlD
Pazopanib—Abdominal pain—Etoposide—urinary bladder cancer	3.68e-05	0.000565	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—urinary bladder cancer	3.67e-05	0.000564	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—urinary bladder cancer	3.67e-05	0.000564	CcSEcCtD
Pazopanib—Diarrhoea—Fluorouracil—urinary bladder cancer	3.66e-05	0.000563	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—urinary bladder cancer	3.65e-05	0.000561	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—urinary bladder cancer	3.64e-05	0.00056	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—urinary bladder cancer	3.64e-05	0.00056	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—urinary bladder cancer	3.62e-05	0.000557	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—urinary bladder cancer	3.62e-05	0.000556	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—urinary bladder cancer	3.61e-05	0.000555	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—urinary bladder cancer	3.61e-05	0.000555	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—urinary bladder cancer	3.6e-05	0.000553	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	3.58e-05	0.00055	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—urinary bladder cancer	3.57e-05	0.000549	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—urinary bladder cancer	3.56e-05	0.000547	CcSEcCtD
Pazopanib—Dizziness—Fluorouracil—urinary bladder cancer	3.54e-05	0.000545	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.53e-05	0.000543	CcSEcCtD
Pazopanib—Chills—Methotrexate—urinary bladder cancer	3.52e-05	0.000541	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—urinary bladder cancer	3.47e-05	0.000534	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—urinary bladder cancer	3.47e-05	0.000533	CcSEcCtD
Pazopanib—Vomiting—Gemcitabine—urinary bladder cancer	3.46e-05	0.000533	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—urinary bladder cancer	3.46e-05	0.000532	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—urinary bladder cancer	3.44e-05	0.000528	CcSEcCtD
Pazopanib—Rash—Gemcitabine—urinary bladder cancer	3.43e-05	0.000528	CcSEcCtD
Pazopanib—Dermatitis—Gemcitabine—urinary bladder cancer	3.43e-05	0.000528	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—urinary bladder cancer	3.43e-05	0.000527	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—urinary bladder cancer	3.41e-05	0.000525	CcSEcCtD
Pazopanib—Erythema—Methotrexate—urinary bladder cancer	3.41e-05	0.000525	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—urinary bladder cancer	3.41e-05	0.000525	CcSEcCtD
Pazopanib—Headache—Gemcitabine—urinary bladder cancer	3.41e-05	0.000525	CcSEcCtD
Pazopanib—Flushing—Epirubicin—urinary bladder cancer	3.41e-05	0.000524	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—urinary bladder cancer	3.41e-05	0.000524	CcSEcCtD
Pazopanib—Vomiting—Fluorouracil—urinary bladder cancer	3.41e-05	0.000524	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—urinary bladder cancer	3.4e-05	0.000522	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.38e-05	0.00052	CcSEcCtD
Pazopanib—Rash—Fluorouracil—urinary bladder cancer	3.38e-05	0.000519	CcSEcCtD
Pazopanib—Dermatitis—Fluorouracil—urinary bladder cancer	3.37e-05	0.000519	CcSEcCtD
Pazopanib—Headache—Fluorouracil—urinary bladder cancer	3.36e-05	0.000516	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.35e-05	0.000516	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.35e-05	0.000514	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—urinary bladder cancer	3.34e-05	0.000514	CcSEcCtD
Pazopanib—Asthenia—Etoposide—urinary bladder cancer	3.34e-05	0.000513	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.34e-05	0.000513	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—urinary bladder cancer	3.33e-05	0.000512	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—urinary bladder cancer	3.33e-05	0.000512	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.31e-05	0.000509	CcSEcCtD
Pazopanib—Chills—Epirubicin—urinary bladder cancer	3.29e-05	0.000506	CcSEcCtD
Pazopanib—Pruritus—Etoposide—urinary bladder cancer	3.29e-05	0.000506	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—urinary bladder cancer	3.24e-05	0.000499	CcSEcCtD
Pazopanib—Nausea—Gemcitabine—urinary bladder cancer	3.24e-05	0.000498	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—urinary bladder cancer	3.23e-05	0.000496	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—urinary bladder cancer	3.22e-05	0.000495	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—urinary bladder cancer	3.22e-05	0.000494	CcSEcCtD
Pazopanib—Rash—Cisplatin—urinary bladder cancer	3.2e-05	0.000492	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—urinary bladder cancer	3.2e-05	0.000492	CcSEcCtD
Pazopanib—Erythema—Epirubicin—urinary bladder cancer	3.2e-05	0.000491	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—urinary bladder cancer	3.2e-05	0.000491	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—urinary bladder cancer	3.18e-05	0.000489	CcSEcCtD
Pazopanib—Nausea—Fluorouracil—urinary bladder cancer	3.18e-05	0.000489	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—urinary bladder cancer	3.17e-05	0.000488	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—urinary bladder cancer	3.16e-05	0.000485	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—urinary bladder cancer	3.15e-05	0.000485	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.15e-05	0.000485	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—urinary bladder cancer	3.15e-05	0.000484	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—urinary bladder cancer	3.13e-05	0.000481	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—urinary bladder cancer	3.08e-05	0.000474	CcSEcCtD
Pazopanib—Dizziness—Etoposide—urinary bladder cancer	3.08e-05	0.000473	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—urinary bladder cancer	3.07e-05	0.000472	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.06e-05	0.000471	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—urinary bladder cancer	3.06e-05	0.00047	CcSEcCtD
Pazopanib—Chills—Doxorubicin—urinary bladder cancer	3.05e-05	0.000469	CcSEcCtD
Pazopanib—Nausea—Cisplatin—urinary bladder cancer	3.02e-05	0.000464	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—urinary bladder cancer	3.01e-05	0.000463	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—urinary bladder cancer	3e-05	0.000461	CcSEcCtD
Pazopanib—Cough—Methotrexate—urinary bladder cancer	2.98e-05	0.000458	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—urinary bladder cancer	2.98e-05	0.000457	CcSEcCtD
Pazopanib—Vomiting—Etoposide—urinary bladder cancer	2.96e-05	0.000455	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—urinary bladder cancer	2.96e-05	0.000455	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—urinary bladder cancer	2.96e-05	0.000455	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—urinary bladder cancer	2.95e-05	0.000454	CcSEcCtD
Pazopanib—Rash—Etoposide—urinary bladder cancer	2.93e-05	0.000451	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—urinary bladder cancer	2.93e-05	0.000451	CcSEcCtD
Pazopanib—Headache—Etoposide—urinary bladder cancer	2.91e-05	0.000448	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—urinary bladder cancer	2.91e-05	0.000448	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—urinary bladder cancer	2.91e-05	0.000447	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—urinary bladder cancer	2.91e-05	0.000447	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—urinary bladder cancer	2.91e-05	0.000447	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—urinary bladder cancer	2.9e-05	0.000445	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.89e-05	0.000444	CcSEcCtD
Pazopanib—Syncope—Epirubicin—urinary bladder cancer	2.87e-05	0.000441	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—urinary bladder cancer	2.86e-05	0.00044	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—urinary bladder cancer	2.84e-05	0.000437	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—urinary bladder cancer	2.81e-05	0.000432	CcSEcCtD
Pazopanib—Cough—Epirubicin—urinary bladder cancer	2.79e-05	0.000429	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—urinary bladder cancer	2.79e-05	0.000428	CcSEcCtD
Pazopanib—Infection—Methotrexate—urinary bladder cancer	2.77e-05	0.000426	CcSEcCtD
Pazopanib—Nausea—Etoposide—urinary bladder cancer	2.76e-05	0.000425	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—urinary bladder cancer	2.76e-05	0.000424	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—urinary bladder cancer	2.73e-05	0.00042	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—urinary bladder cancer	2.73e-05	0.00042	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.73e-05	0.000419	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—urinary bladder cancer	2.72e-05	0.000418	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—urinary bladder cancer	2.72e-05	0.000418	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—urinary bladder cancer	2.72e-05	0.000418	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—urinary bladder cancer	2.71e-05	0.000416	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.7e-05	0.000415	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.69e-05	0.000414	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—urinary bladder cancer	2.66e-05	0.000409	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—urinary bladder cancer	2.66e-05	0.000408	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—urinary bladder cancer	2.65e-05	0.000408	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—urinary bladder cancer	2.65e-05	0.000407	CcSEcCtD
Pazopanib—Oedema—Epirubicin—urinary bladder cancer	2.61e-05	0.000401	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—urinary bladder cancer	2.6e-05	0.0004	CcSEcCtD
Pazopanib—Infection—Epirubicin—urinary bladder cancer	2.59e-05	0.000398	CcSEcCtD
Pazopanib—Cough—Doxorubicin—urinary bladder cancer	2.58e-05	0.000397	CcSEcCtD
Pazopanib—Shock—Epirubicin—urinary bladder cancer	2.57e-05	0.000394	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—urinary bladder cancer	2.56e-05	0.000393	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.55e-05	0.000393	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—urinary bladder cancer	2.55e-05	0.000392	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.54e-05	0.00039	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—urinary bladder cancer	2.53e-05	0.000389	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.52e-05	0.000388	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—urinary bladder cancer	2.52e-05	0.000387	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—urinary bladder cancer	2.52e-05	0.000387	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—urinary bladder cancer	2.52e-05	0.000387	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—urinary bladder cancer	2.52e-05	0.000387	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—urinary bladder cancer	2.5e-05	0.000385	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.5e-05	0.000384	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—urinary bladder cancer	2.49e-05	0.000382	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—urinary bladder cancer	2.48e-05	0.000382	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—urinary bladder cancer	2.48e-05	0.000381	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—urinary bladder cancer	2.46e-05	0.000378	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—urinary bladder cancer	2.45e-05	0.000377	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—urinary bladder cancer	2.42e-05	0.000372	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—urinary bladder cancer	2.41e-05	0.000371	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.41e-05	0.00037	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—urinary bladder cancer	2.4e-05	0.000369	CcSEcCtD
Pazopanib—Infection—Doxorubicin—urinary bladder cancer	2.4e-05	0.000369	CcSEcCtD
Pazopanib—Pain—Methotrexate—urinary bladder cancer	2.38e-05	0.000366	CcSEcCtD
Pazopanib—ABCB1—lymph node—urinary bladder cancer	2.38e-05	0.000421	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.38e-05	0.000365	CcSEcCtD
Pazopanib—Shock—Doxorubicin—urinary bladder cancer	2.37e-05	0.000365	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.37e-05	0.000364	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.36e-05	0.000363	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—urinary bladder cancer	2.36e-05	0.000363	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—urinary bladder cancer	2.34e-05	0.00036	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—urinary bladder cancer	2.34e-05	0.00036	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.33e-05	0.000359	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—urinary bladder cancer	2.32e-05	0.000357	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—urinary bladder cancer	2.32e-05	0.000356	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—urinary bladder cancer	2.3e-05	0.000354	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—urinary bladder cancer	2.3e-05	0.000353	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.28e-05	0.00035	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—urinary bladder cancer	2.27e-05	0.000349	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.25e-05	0.000346	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—urinary bladder cancer	2.25e-05	0.000346	CcSEcCtD
Pazopanib—Pain—Epirubicin—urinary bladder cancer	2.23e-05	0.000343	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—urinary bladder cancer	2.2e-05	0.000339	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.2e-05	0.000338	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—urinary bladder cancer	2.18e-05	0.000336	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—urinary bladder cancer	2.17e-05	0.000333	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—urinary bladder cancer	2.15e-05	0.000331	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—urinary bladder cancer	2.14e-05	0.00033	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.13e-05	0.000328	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—urinary bladder cancer	2.12e-05	0.000327	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—urinary bladder cancer	2.1e-05	0.000322	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.08e-05	0.00032	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—urinary bladder cancer	2.08e-05	0.00032	CcSEcCtD
Pazopanib—Pain—Doxorubicin—urinary bladder cancer	2.06e-05	0.000317	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—urinary bladder cancer	2.06e-05	0.000317	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—urinary bladder cancer	2e-05	0.000307	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.97e-05	0.000303	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—urinary bladder cancer	1.97e-05	0.000303	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—urinary bladder cancer	1.91e-05	0.000293	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—urinary bladder cancer	1.91e-05	0.000293	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—urinary bladder cancer	1.87e-05	0.000288	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—urinary bladder cancer	1.84e-05	0.000284	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—urinary bladder cancer	1.84e-05	0.000283	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—urinary bladder cancer	1.78e-05	0.000274	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—urinary bladder cancer	1.77e-05	0.000272	CcSEcCtD
Pazopanib—Rash—Methotrexate—urinary bladder cancer	1.76e-05	0.00027	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—urinary bladder cancer	1.76e-05	0.00027	CcSEcCtD
Pazopanib—Headache—Methotrexate—urinary bladder cancer	1.75e-05	0.000268	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—urinary bladder cancer	1.73e-05	0.000266	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—urinary bladder cancer	1.72e-05	0.000265	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—urinary bladder cancer	1.71e-05	0.000262	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—urinary bladder cancer	1.66e-05	0.000255	CcSEcCtD
Pazopanib—Nausea—Methotrexate—urinary bladder cancer	1.66e-05	0.000254	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—urinary bladder cancer	1.65e-05	0.000254	CcSEcCtD
Pazopanib—Rash—Epirubicin—urinary bladder cancer	1.64e-05	0.000253	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—urinary bladder cancer	1.64e-05	0.000253	CcSEcCtD
Pazopanib—Headache—Epirubicin—urinary bladder cancer	1.63e-05	0.000251	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—urinary bladder cancer	1.6e-05	0.000245	CcSEcCtD
Pazopanib—Nausea—Epirubicin—urinary bladder cancer	1.55e-05	0.000238	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—urinary bladder cancer	1.53e-05	0.000236	CcSEcCtD
Pazopanib—Rash—Doxorubicin—urinary bladder cancer	1.52e-05	0.000234	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—urinary bladder cancer	1.52e-05	0.000234	CcSEcCtD
Pazopanib—Headache—Doxorubicin—urinary bladder cancer	1.51e-05	0.000232	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—urinary bladder cancer	1.43e-05	0.00022	CcSEcCtD
Pazopanib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.49e-06	2.04e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—urinary bladder cancer	1.49e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FGFR3—urinary bladder cancer	1.49e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL2—urinary bladder cancer	1.49e-06	2.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—urinary bladder cancer	1.49e-06	2.03e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—urinary bladder cancer	1.49e-06	2.03e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—urinary bladder cancer	1.48e-06	2.03e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.48e-06	2.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—urinary bladder cancer	1.48e-06	2.02e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—urinary bladder cancer	1.47e-06	2.01e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CXCL8—urinary bladder cancer	1.47e-06	2.01e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.47e-06	2.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—urinary bladder cancer	1.47e-06	2.01e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.46e-06	2e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—urinary bladder cancer	1.46e-06	1.99e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—urinary bladder cancer	1.45e-06	1.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—urinary bladder cancer	1.45e-06	1.99e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—urinary bladder cancer	1.45e-06	1.98e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	1.45e-06	1.98e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.44e-06	1.98e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.44e-06	1.97e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.44e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—urinary bladder cancer	1.43e-06	1.96e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RHOA—urinary bladder cancer	1.43e-06	1.95e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-06	1.95e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—urinary bladder cancer	1.42e-06	1.95e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—urinary bladder cancer	1.42e-06	1.94e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.42e-06	1.94e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—urinary bladder cancer	1.42e-06	1.94e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	1.42e-06	1.94e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—urinary bladder cancer	1.41e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CDKN1A—urinary bladder cancer	1.4e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTEN—urinary bladder cancer	1.4e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RHOA—urinary bladder cancer	1.4e-06	1.91e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CXCL8—urinary bladder cancer	1.4e-06	1.91e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—urinary bladder cancer	1.39e-06	1.91e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.39e-06	1.91e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CXCL8—urinary bladder cancer	1.39e-06	1.9e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—urinary bladder cancer	1.39e-06	1.9e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—urinary bladder cancer	1.39e-06	1.9e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—urinary bladder cancer	1.38e-06	1.88e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—urinary bladder cancer	1.37e-06	1.88e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—urinary bladder cancer	1.37e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—urinary bladder cancer	1.36e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—urinary bladder cancer	1.35e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.35e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTEN—urinary bladder cancer	1.35e-06	1.84e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—urinary bladder cancer	1.34e-06	1.83e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.34e-06	1.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—urinary bladder cancer	1.34e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—urinary bladder cancer	1.34e-06	1.83e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—urinary bladder cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EP300—urinary bladder cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—urinary bladder cancer	1.33e-06	1.82e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—urinary bladder cancer	1.33e-06	1.82e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—urinary bladder cancer	1.33e-06	1.82e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CDKN1A—urinary bladder cancer	1.33e-06	1.81e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—urinary bladder cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTEN—urinary bladder cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—urinary bladder cancer	1.31e-06	1.79e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—urinary bladder cancer	1.31e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—urinary bladder cancer	1.31e-06	1.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—urinary bladder cancer	1.3e-06	1.78e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	1.3e-06	1.78e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—SRC—urinary bladder cancer	1.3e-06	1.78e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	1.3e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CDKN1A—urinary bladder cancer	1.3e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.29e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTEN—urinary bladder cancer	1.29e-06	1.77e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EP300—urinary bladder cancer	1.28e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-06	1.75e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.27e-06	1.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	1.27e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—urinary bladder cancer	1.27e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—urinary bladder cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—urinary bladder cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EP300—urinary bladder cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	1.26e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.26e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTEN—urinary bladder cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—urinary bladder cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	1.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	1.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—urinary bladder cancer	1.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SRC—urinary bladder cancer	1.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.24e-06	1.7e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.24e-06	1.7e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—urinary bladder cancer	1.24e-06	1.69e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—urinary bladder cancer	1.24e-06	1.69e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—urinary bladder cancer	1.23e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EP300—urinary bladder cancer	1.23e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.23e-06	1.68e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SRC—urinary bladder cancer	1.23e-06	1.68e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—SRC—urinary bladder cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EP300—urinary bladder cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	1.19e-06	1.63e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	1.19e-06	1.63e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.18e-06	1.62e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.18e-06	1.61e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—urinary bladder cancer	1.17e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—urinary bladder cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—urinary bladder cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-06	1.59e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—urinary bladder cancer	1.16e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SRC—urinary bladder cancer	1.16e-06	1.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	1.16e-06	1.59e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.15e-06	1.57e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.15e-06	1.57e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	1.15e-06	1.57e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	1.14e-06	1.57e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.14e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—urinary bladder cancer	1.14e-06	1.56e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—urinary bladder cancer	1.14e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	1.13e-06	1.55e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	1.13e-06	1.55e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	1.13e-06	1.55e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-06	1.54e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—urinary bladder cancer	1.12e-06	1.53e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—urinary bladder cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—urinary bladder cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—urinary bladder cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.11e-06	1.51e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.1e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	1.1e-06	1.51e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.1e-06	1.5e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—urinary bladder cancer	1.1e-06	1.5e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-06	1.5e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.09e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.09e-06	1.49e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.08e-06	1.48e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—urinary bladder cancer	1.08e-06	1.48e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	1.08e-06	1.47e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—urinary bladder cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—urinary bladder cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—urinary bladder cancer	1.06e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	1.06e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—urinary bladder cancer	1.05e-06	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—urinary bladder cancer	1.05e-06	1.44e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—urinary bladder cancer	1.05e-06	1.44e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.05e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	1.05e-06	1.43e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—urinary bladder cancer	1.04e-06	1.43e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.04e-06	1.42e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	1.04e-06	1.42e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-06	1.41e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.02e-06	1.4e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.02e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-06	1.4e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	1.01e-06	1.38e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1e-06	1.37e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—urinary bladder cancer	1e-06	1.37e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—urinary bladder cancer	9.92e-07	1.36e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.69e-07	1.33e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—urinary bladder cancer	9.63e-07	1.32e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—urinary bladder cancer	9.62e-07	1.32e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	9.61e-07	1.32e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.6e-07	1.31e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	9.48e-07	1.3e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	9.37e-07	1.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	9.37e-07	1.28e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	9.31e-07	1.27e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.27e-07	1.27e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	9.2e-07	1.26e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	9.2e-07	1.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—urinary bladder cancer	9.19e-07	1.26e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—urinary bladder cancer	9.17e-07	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	9.16e-07	1.25e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—urinary bladder cancer	9.13e-07	1.25e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.11e-07	1.25e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	9.1e-07	1.25e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	9.07e-07	1.24e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	9.05e-07	1.24e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—urinary bladder cancer	9.02e-07	1.23e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	8.97e-07	1.23e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	8.81e-07	1.21e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—urinary bladder cancer	8.79e-07	1.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	8.66e-07	1.18e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	8.65e-07	1.18e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	8.63e-07	1.18e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—urinary bladder cancer	8.63e-07	1.18e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—urinary bladder cancer	8.56e-07	1.17e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	8.54e-07	1.17e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	8.48e-07	1.16e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—urinary bladder cancer	8.43e-07	1.15e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—urinary bladder cancer	8.39e-07	1.15e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.26e-07	1.13e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—urinary bladder cancer	8.19e-07	1.12e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	8.17e-07	1.12e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	8.13e-07	1.11e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.94e-07	1.09e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.78e-07	1.07e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.73e-07	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	7.69e-07	1.05e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—urinary bladder cancer	7.53e-07	1.03e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—urinary bladder cancer	7.52e-07	1.03e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.48e-07	1.02e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	7.46e-07	1.02e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	7.36e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	7.35e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	7.2e-07	9.86e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.18e-07	9.83e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.1e-07	9.72e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.1e-07	9.72e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	6.95e-07	9.51e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.8e-07	9.31e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.68e-07	9.14e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	6.59e-07	9.03e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.51e-07	8.9e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.5e-07	8.89e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.34e-07	8.67e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.28e-07	8.59e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.2e-07	8.49e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—urinary bladder cancer	6.18e-07	8.45e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.12e-07	8.38e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	5.91e-07	8.08e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.67e-07	7.76e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—urinary bladder cancer	5.4e-07	7.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.34e-07	7.31e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.19e-07	7.1e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.09e-07	6.97e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.09e-07	6.97e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.89e-07	6.69e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.52e-07	6.19e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.31e-07	5.9e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4e-07	5.48e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.49e-07	4.78e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.33e-07	4.56e-06	CbGpPWpGaD
